Cell reprogramming — the technique of returning adult cells to a more youthful state using four genetic factors identified in Nobel Prize-winning research — has become the buzziest approach in longevity science, displacing earlier obsessions with telomere lengthening and senolytic drugs.
The first human trial arrives
The shift from animal studies to human medicine reached a marker last week. Life Biosciences dosed its first patient in a Phase 1 trial of ER-100, an experimental therapy injected directly into the eyeball to treat optic neuropathies including open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy. The drug uses controlled expression of three transcription factors — OCT4, SOX2 and KLF4, collectively known as OSK — to reset the epigenetic patterns of retinal ganglion cells.
David Sinclair, the Harvard geneticist who co-founded Life Bio, has framed the trial in characteristically expansive terms. If the treatment can reverse glaucoma, perhaps similar treatments can reverse other diseases of aging — and maybe, just maybe, they can reverse aging altogether.
Where the money is going
The capital flowing into reprogramming startups dwarfs prior longevity bets. Altos Labs launched in 2022 with $3bn in initial funding from backers including Yuri Milner and, reportedly, Jeff Bezos — a sum unprecedented for a biotech startup at launch. Retro Biosciences was seeded with $180m from OpenAI’s Sam Altman. NewLimit, co-founded by Coinbase’s Brian Armstrong, has raised roughly $170m across its rounds. Life Biosciences itself has raised more than $100m and is competing for a $101m XPrize Foundation purse for age-reversal therapies.
The investor profile is worth pausing on. The cheques are being written largely by figures whose fortunes were built in software and platform monopolies — Altman, Bezos, Milner — rather than by the pharmaceutical sector that has historically funded drug development. That distinction shapes incentives. Software capital tends to underwrite winner-take-all moonshots; pharmaceutical capital tends to underwrite incremental, regulated returns. The reprogramming boom is being priced on the former logic and will be regulated under the latter.
The graveyard of previous paradigms
Reprogramming has become dominant partly because earlier approaches have disappointed. Telomere-lengthening therapies — the trend that prompted BioViva CEO Liz Parrish to inject herself with experimental gene therapy in 2015, later making bold claims about being among the most genetically modified humans — produced few clinical wins.
Senolytic drugs, which clear out aged “zombie” cells, generated excitement after a 2011 mouse study showed that clearing p16Ink4a-positive senescent cells in a progeroid mouse model delayed the onset of several age-associated disorders. But translation to humans has been rough. Unity Biotechnology, once the leading senolytics company, saw its shares fall 46% in premarket trading after its lead asset UBX1325 failed to show non-inferiority to Regeneron’s Eylea in a Phase II wet age-related macular degeneration trial. The company later continued work in diabetic macular oedema, but the broader commercial story still illustrates the problem: a platform that looked powerful in aging biology became much harder to defend once it had to beat entrenched eye-disease standards in regulated human trials.
The structural question
The reprogramming thesis rests on the idea — articulated in the seminal 2013 paper on the hallmarks of aging — that biological decline is driven less by accumulated damage than by lost epigenetic information that can, in principle, be rewritten. Mouse studies have shown tissue healing, vision restoration, and cognitive improvement. Whether the biology translates to humans is the empirical question. Whether the funding model survives if it doesn’t is the institutional one.
